Trial Profile

Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-Positive Endometrioid Endometrial Cancers

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alpelisib (Primary) ; Fulvestrant (Primary)
Indications Carcinoma; Endometrial cancer
Focus Therapeutic Use

Most Recent Events

03 Mar 2026 Planned End Date changed from 1 Apr 2026 to 1 Nov 2028.
03 Mar 2026 Planned primary completion date changed from 1 Apr 2025 to 11 May 2028.
03 Mar 2026 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com